OPTIMA Trial: Genomic Testing May Allow Some High-Risk Breast Cancer Patients to Skip Chemotherapy
By
Meredith Begley
Summary
The OPTIMA phase 3 trial, presented at the 2026 ASCO annual meeting, found that some women with high-risk, ER-positive, HER2-negative early breast cancer may be able to safely avoid chemotherapy. The study evaluated patients with up to nine positive lymph nodes or tumors of at least 30mm — groups historically given chemotherapy due to high clinical risk. The findings suggest that genomic testing could help identify which patients can forgo chemo without compromising outcomes.
Source
bskyOPTIMA Trial: Genomic Testing May Allow Some High-Risk Breast Cancer Patients to Skip Chemotherapybcrf.orgKey quotes
· 3 pulledThe phase 3 trial evaluated people with this type of breast cancer who had up to nine positive lymph nodes or a tumor size of at least 30 mm.
Historically, many of these patients would routinely receive chemotherapy because of their high clinical risk.
Some women with high-risk, ER-positive, HER2-negative early breast cancer may be able to safely avoid chemotherapy, according to results from the OPTIMA trial presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting.
You might also wanna read
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features in
mdsc.pe·5d ago
Why a cancer researcher with a high genetic risk wants AI development to slow down
A personal essay from someone with a high genetic cancer risk who has spent years working toward AI-driven cancer detection. Despite persona
theatlantic.com·19h agoWhy a cancer researcher with a high genetic risk wants AI development to slow down
A personal essay from someone with a high genetic cancer risk who has spent years working toward AI-driven cancer detection. Despite persona
theatlantic.com·19h ago
Breast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutations
This article appears to be a medical education piece focused on breast cancer treatment strategies, specifically discussing patients progres
mdsc.pe·1d ago
New Tool Predicts Heart Failure Risk in Breast Cancer Survivors
Breast cancer treatments can increase the risk of heart issues, and researchers have developed a new tool to predict which survivors are mos
breastcancer.org·4d ago
Galleri Blood Test Shows Promise in Detecting 50 Types of Cancer in Large Clinical Trial
A large-scale clinical trial of the Galleri blood test, which detects cancer DNA fragments in blood, showed promising results with 25,000 pa
bbc.com·8mo ago
CCR study reveals how leukemia chemotherapy drug Ara-C damages neurons causing balance problems
CCR scientists led by Andre Nussenzweig have discovered why the chemotherapy drug Ara-C (used to treat blood cancers) causes movement and ba
go.nih.gov·1d agoComments
Sign in to join the conversation.
No comments yet. Be the first.